Yahoo
OTC Markets OTCQB - Delayed Quote USD

Medicenna Therapeutics Corp. (MDNAF)

0.3070 +0.0230 (+8.10%)
As of October 23 at 4:00:00 PM EDT. Market Open.
Chart Range Bar
Loading chart for MDNAF
  • Previous Close 0.2840
  • Open 0.3132
  • Bid 0.2912 x 1000000
  • Ask 0.3122 x 2000000
  • Day's Range 0.3114 - 0.3132
  • 52 Week Range 0.2290 - 1.4300
  • Volume 5,500
  • Avg. Volume 44,535
  • Market Cap (intraday) 28.336M
  • Beta (5Y Monthly) 2.10
  • PE Ratio (TTM) --
  • EPS (TTM) -0.1600
  • Earnings Date (est.) Nov 12, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 4.25
  • Zacks Rating Neutral

Medicenna Therapeutics Corp., a clinical-stage immunotherapy company, engages in the development and commercialization of Superkines and empowered Superkines for the treatment of cancer, inflammation, and immune-mediated diseases. It develops bizaxofusp, an interleukin- 4 (IL-4) targeted therapy for the treatment of recurrent glioblastoma. The company also develops MDNA11, an interleukin-2 (IL-2) to activate anti-cancer immune cells over immunosuppressive Tregs; and MDNA113, a tumor-targeting and activatable bifunctional anti-PD-1-IL-2 superkine for cancer. In addition, its preclinical products are MDNA209, an IL-2/IL-15 antagonist for autoimmune diseases, such as multiple sclerosis and graft versus host diseases, including transplant rejection; and MDNA413, an IL-4/IL-13 antagonist to inflammatory, asthma, and atopic dermatitis, as well as other allergic diseases. Medicenna Therapeutics Corp. is headquartered in Toronto, Canada.

www.medicenna.com

15

Full Time Employees

March 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/26/2026, which may include dividends or other distributions. Benchmark is S&P/TSX Composite index (^GSPTSE) .

YTD Return

MDNAF
55.51%
S&P/TSX Composite index (^GSPTSE)
12.61%

1-Year Return

MDNAF
72.09%
S&P/TSX Composite index (^GSPTSE)
18.23%

3-Year Return

MDNAF
22.31%
S&P/TSX Composite index (^GSPTSE)
90.12%

5-Year Return

MDNAF
86.17%
S&P/TSX Composite index (^GSPTSE)
69.49%

Earnings Trends

View More

Earnings Per Share (GAAP)

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY26
Revenue --
Earnings -4.23M
Profit Margin 0.00%

Q1

FY26

Q2

FY26

Q3

FY26

Q4

FY26

-4M
-3M
-2M
-1M
0
0.0%

Analyst Insights

View More

Analyst Price Targets

2.50
4.25 Average
0.3070 Current
6.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 12/6/2024
Analyst HC Wainwright & Co.
Rating Action Reiterates
Rating Buy
Price Action Maintains
Price Target 2.5 -> 2.5

Statistics

View More

Valuation Measures

Annual
As of 10/23/2026
  • Market Cap

    27.93M

  • Enterprise Value

    23.95M

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    23.76

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -90.10%

  • Return on Equity (ttm)

    -227.57%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -18.56M

  • Diluted EPS (ttm)

    -0.1600

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    5.69M

  • Total Debt/Equity (mrq)

    6.22%

  • Levered Free Cash Flow (ttm)

    -10.79M

Compare

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights

Fair Value

0.3070 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: